Literature DB >> 17910038

Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion.

Michael P Sanderson1, Sascha Keller, Angel Alonso, Svenja Riedle, Peter J Dempsey, Peter Altevogt.   

Abstract

Exosomes are small membrane vesicles derived from intracellular multivescicular bodies (MVBs) that can undergo constitutive and regulated secretion from cells. Exosomes can also secrete soluble proteins through metalloprotease-dependent ectodomain shedding. In this study, we sought to determine whether ErbB1 receptors are present within exosomes isolated from the human keratinocyte cell line, HaCaT, and whether exosome-associated ErbB1 receptors can undergo further proteolytic processing. We show that full-length transmembrane ErbB1 is secreted in HaCaT exosomes. EGF treatment and calcium flux stimulated the release of phosphorylated ErbB1 in exosomes but only ligand-stimulated release was blocked by the ErbB1 kinase inhibitor, AG1478, indicating that ligand-dependent ErbB1 receptor activation can initiate ErbB1 secretion into exosomes. In addition, other immunoreactive but truncated ErbB1 isoforms were detected in exosomes suggestive of additional proteolytic processing. We demonstrate that cellular and exosomal ErbB1 receptors can undergo ectodomain shedding to generate soluble N-terminal ectodomains and membrane-associated C-terminal remnant fragments (CTFs). ErbB1 shedding was activated by calcium flux and the metalloprotease activator APMA (4-aminophenylmercuric acetate) and was blocked by a metalloprotease inhibitor (GM6001). Soluble ErbB1 ectodomains shed into conditioned medium retained the ability to bind exogenous ligand. Our results provide new insights into the proteolysis, trafficking and fate of ErbB1 receptors and suggest that the novel ErbB1 isoforms may have functions distinct from the plasma membrane receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17910038      PMCID: PMC4922250          DOI: 10.1002/jcb.21569

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  56 in total

Review 1.  Exosome secretion: the art of reutilizing nonrecycled proteins?

Authors:  Aude de Gassart; Charles Géminard; Dick Hoekstra; Michel Vidal
Journal:  Traffic       Date:  2004-11       Impact factor: 6.215

2.  Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.

Authors:  Xiangdong Liu; Jordan S Fridman; Qian Wang; Eian Caulder; Gengjie Yang; Maryanne Covington; Changnian Liu; Cindy Marando; Jincong Zhuo; Yanlong Li; Wenqing Yao; Kris Vaddi; Robert C Newton; Peggy A Scherle; Steven M Friedman
Journal:  Cancer Biol Ther       Date:  2006-06-14       Impact factor: 4.742

Review 3.  Exosomes biological significance: A concise review.

Authors:  Rose M Johnstone
Journal:  Blood Cells Mol Dis       Date:  2006-02-17       Impact factor: 3.039

4.  The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT.

Authors:  K Crusius; E Auvinen; B Steuer; H Gaissert; A Alonso
Journal:  Exp Cell Res       Date:  1998-05-25       Impact factor: 3.905

5.  ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles.

Authors:  Paul Gutwein; Sabine Mechtersheimer; Svenja Riedle; Alexander Stoeck; Daniela Gast; Safwan Joumaa; Hanswalter Zentgraf; Mina Fogel; D Peter Altevogt
Journal:  FASEB J       Date:  2002-12-03       Impact factor: 5.191

Review 6.  Annexins: linking Ca2+ signalling to membrane dynamics.

Authors:  Volker Gerke; Carl E Creutz; Stephen E Moss
Journal:  Nat Rev Mol Cell Biol       Date:  2005-06       Impact factor: 94.444

7.  Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process.

Authors:  A Pandiella; J Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

8.  Nuclear localization of EGF receptor and its potential new role as a transcription factor.

Authors:  S Y Lin; K Makino; W Xia; A Matin; Y Wen; K Y Kwong; L Bourguignon; M C Hung
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

9.  Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body.

Authors:  S Felder; K Miller; G Moehren; A Ullrich; J Schlessinger; C R Hopkins
Journal:  Cell       Date:  1990-05-18       Impact factor: 41.582

10.  Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form.

Authors:  Juha Hakulinen; Sami Junnikkala; Timo Sorsa; Seppo Meri
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

View more
  48 in total

Review 1.  Molecular mechanisms of soluble cytokine receptor generation.

Authors:  Stewart J Levine
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

Review 2.  Microvesicles: mediators of extracellular communication during cancer progression.

Authors:  Vandhana Muralidharan-Chari; James W Clancy; Alanna Sedgwick; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2010-05-15       Impact factor: 5.285

3.  EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.

Authors:  Shaorong Yu; Huanhuan Sha; Xiaobing Qin; Yan Chen; Xiaoyou Li; Meiqi Shi; Jifeng Feng
Journal:  Oncogene       Date:  2020-01-30       Impact factor: 9.867

Review 4.  Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.

Authors:  Miles A Miller; Ryan J Sullivan; Douglas A Lauffenburger
Journal:  Clin Cancer Res       Date:  2016-11-28       Impact factor: 12.531

5.  Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients.

Authors:  Hana Polanska; Martina Raudenska; Kristyna Hudcová; Jaromir Gumulec; Marketa Svobodova; Zbynek Heger; Michaela Fojtu; Hana Binkova; Zuzana Horakova; Rom Kostrica; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  Oncol Lett       Date:  2016-07-21       Impact factor: 2.967

6.  Immunotherapy strategy of EGFR mutant lung cancer.

Authors:  Shaorong Yu; Delin Liu; Bo Shen; Meiqi Shi; Jifeng Feng
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

7.  Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.

Authors:  Khalid Al-Nedawi; Brian Meehan; Robert S Kerbel; Anthony C Allison; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

8.  Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes.

Authors:  Andrew M Overmiller; Jennifer A Pierluissi; Peter J Wermuth; Sami Sauma; Ubaldo Martinez-Outschoorn; Madalina Tuluc; Adam Luginbuhl; Joseph Curry; Larry A Harshyne; James K Wahl; Andrew P South; Mỹ G Mahoney
Journal:  FASEB J       Date:  2017-04-24       Impact factor: 5.191

9.  A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.

Authors:  Yasuhide Yamada; Naomi Kiyota; Nozomu Fuse; Ken Kato; Hironobu Minami; Kensei Hashizume; Yoshihiro Kuroki; Yuichiro Ito; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2013-03-27       Impact factor: 7.370

10.  P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways.

Authors:  Yan Qu; George R Dubyak
Journal:  Purinergic Signal       Date:  2009-02-03       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.